Document Type
Article
Embargo Period
1-1-2024
Publication Date
4-1-2001
Abstract
The relative potency and tolerability of multidrug regimens used to treat infants and children infected with human immunodeficiency virus type 1 (HIV-1) are largely unknown. In Pediatric AIDS Clinical Trials Group (PACTG) Protocol 377, 181 infants and children were assigned to receive stavudine (d4T) plus nevirapine (NVP) and ritonavir (RTV); d4T plus lamivudine (3TC) and nelfinavir (NFV); d4T plus NVP and NFV; or d4T plus 3TC, NVP, and NFV. Eleven additional children received d4T and NVP plus NFV given twice daily. All subjects had not previously received protease inhibitors or nonnucleoside reverse-transcriptase inhibitors and all had been immunologically stable while receiving reverse-transcriptase inhibitor therapy. After 48 weeks of therapy, 17 (41%) of 41 subjects receiving d4T-NVP-RTV, 13 (30%) of 44 receiving d4T-NVP-NFV, 21 (42%) of 50 receiving d4T-3TC and NFV (3 times daily), and 22 (52%) of 42 receiving d4T-3TC-NVP-NFV were still receiving their assigned therapy and had HIV-1 RNA suppression to ≤400 copies/mL. These regimens were similar in their drug activity, but the 4-drug regimen offered slightly more durable suppression of viremia.
Journal
Clinical Infectious Diseases
DOI
doi: 10.1086/338814
Recommended Citation
Krogstad, Paul; Lee, Sophia; Johnson, George; Stanley, Kenneth; McNamara, James; Moye, John; Jackson, J. Brooks; Aguayo, Rosaura; Dieudonne, Arry; Khoury, Margaret; Mendez, Hermann; Nachman, Sharon; Wiznia, Andrew; and Pediatric AIDS Clinical Trials Group 377 Study Team, "Nucleoside-Analogue Reverse-Transcriptase Inhibitors Plus Nevirapine, Nelfinavir or Ritonavir for Pretreated Children Infected with Human Immunodeficiency Virus Type 1" (2001). MUSC Faculty Journal Articles. 125.
https://medica-musc.researchcommons.org/facarticles/125